| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian virus 40 | 146 | 2019 | 197 | 15.550 |
Why?
|
| Polyomavirus Infections | 42 | 2019 | 90 | 7.900 |
Why?
|
| Tumor Virus Infections | 38 | 2016 | 134 | 6.500 |
Why?
|
| DNA, Viral | 72 | 2014 | 481 | 3.810 |
Why?
|
| Antigens, Polyomavirus Transforming | 40 | 2018 | 87 | 3.380 |
Why?
|
| Polyomavirus | 15 | 2014 | 32 | 2.040 |
Why?
|
| Antibodies, Viral | 24 | 2019 | 1146 | 1.770 |
Why?
|
| JC Virus | 13 | 2014 | 29 | 1.710 |
Why?
|
| Antigens, Viral, Tumor | 26 | 2016 | 47 | 1.620 |
Why?
|
| BK Virus | 13 | 2014 | 59 | 1.580 |
Why?
|
| Cell Transformation, Viral | 25 | 2018 | 106 | 1.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2007 | 162 | 1.460 |
Why?
|
| Polymerase Chain Reaction | 28 | 2014 | 1583 | 1.410 |
Why?
|
| Neoplasms | 22 | 2012 | 2786 | 1.240 |
Why?
|
| Mammary Neoplasms, Experimental | 29 | 2001 | 244 | 1.210 |
Why?
|
| RNA, Viral | 15 | 2018 | 538 | 1.140 |
Why?
|
| Base Sequence | 44 | 2014 | 3093 | 1.000 |
Why?
|
| Mammary Tumor Virus, Mouse | 21 | 1995 | 106 | 0.960 |
Why?
|
| Drug Contamination | 11 | 2012 | 36 | 0.950 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 12 | 2010 | 162 | 0.940 |
Why?
|
| Antibodies, Neutralizing | 3 | 2019 | 463 | 0.920 |
Why?
|
| Lymphoma | 5 | 2009 | 322 | 0.910 |
Why?
|
| Cell Line | 65 | 2018 | 2769 | 0.900 |
Why?
|
| Molecular Sequence Data | 40 | 2016 | 3872 | 0.880 |
Why?
|
| Lymphoma, AIDS-Related | 4 | 2005 | 37 | 0.840 |
Why?
|
| Genes, Viral | 25 | 2005 | 184 | 0.840 |
Why?
|
| Virus Shedding | 6 | 2014 | 80 | 0.830 |
Why?
|
| Animals | 154 | 2016 | 34134 | 0.740 |
Why?
|
| Genome, Viral | 8 | 2018 | 168 | 0.720 |
Why?
|
| Oncogenic Viruses | 8 | 2012 | 17 | 0.720 |
Why?
|
| MicroRNAs | 3 | 2018 | 838 | 0.710 |
Why?
|
| Mammary Glands, Animal | 18 | 2001 | 483 | 0.710 |
Why?
|
| Cell Transformation, Neoplastic | 34 | 2007 | 618 | 0.710 |
Why?
|
| Hepatitis B virus | 12 | 1998 | 136 | 0.700 |
Why?
|
| Antigens, Viral | 24 | 2008 | 437 | 0.670 |
Why?
|
| Cricetinae | 34 | 2014 | 411 | 0.670 |
Why?
|
| Herpesvirus 4, Human | 6 | 2009 | 672 | 0.670 |
Why?
|
| Genes, p53 | 10 | 1998 | 213 | 0.660 |
Why?
|
| HIV Infections | 8 | 2010 | 1869 | 0.650 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 4 | 0.650 |
Why?
|
| Brain Neoplasms | 9 | 2004 | 1241 | 0.640 |
Why?
|
| Genetic Variation | 9 | 2012 | 1491 | 0.630 |
Why?
|
| Trans-Activators | 11 | 2001 | 808 | 0.630 |
Why?
|
| Viral Proteins | 20 | 1998 | 349 | 0.600 |
Why?
|
| Viral Load | 8 | 2014 | 381 | 0.600 |
Why?
|
| Poliovirus Vaccines | 5 | 2003 | 14 | 0.590 |
Why?
|
| Papillomavirus Infections | 5 | 1999 | 288 | 0.590 |
Why?
|
| Cell Nucleus | 23 | 1993 | 676 | 0.560 |
Why?
|
| Mice, Inbred BALB C | 38 | 2005 | 1000 | 0.560 |
Why?
|
| Poliovirus Vaccine, Inactivated | 5 | 2005 | 12 | 0.550 |
Why?
|
| Feces | 3 | 2014 | 715 | 0.540 |
Why?
|
| Haplorhini | 24 | 2008 | 123 | 0.520 |
Why?
|
| Lymphocytes | 1 | 2018 | 406 | 0.520 |
Why?
|
| Humans | 118 | 2019 | 124231 | 0.510 |
Why?
|
| Kidney Transplantation | 5 | 2012 | 634 | 0.500 |
Why?
|
| Mesothelioma | 5 | 2007 | 60 | 0.500 |
Why?
|
| Neoplasms, Experimental | 17 | 2004 | 213 | 0.490 |
Why?
|
| Liver Neoplasms | 14 | 2005 | 1319 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2003 | 720 | 0.490 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2009 | 240 | 0.480 |
Why?
|
| Mesocricetus | 10 | 2014 | 71 | 0.480 |
Why?
|
| B-Lymphocytes | 3 | 2018 | 519 | 0.470 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 62 | 0.450 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2009 | 291 | 0.450 |
Why?
|
| Adenoviridae | 25 | 1986 | 604 | 0.440 |
Why?
|
| Pleural Neoplasms | 3 | 2007 | 48 | 0.440 |
Why?
|
| Seroepidemiologic Studies | 6 | 2019 | 121 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2014 | 232 | 0.440 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 10 | 1996 | 369 | 0.440 |
Why?
|
| Lymph Nodes | 4 | 2010 | 376 | 0.430 |
Why?
|
| Mice | 71 | 2007 | 17739 | 0.420 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2003 | 266 | 0.420 |
Why?
|
| Mutation | 29 | 2018 | 5803 | 0.420 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 1998 | 938 | 0.400 |
Why?
|
| Antigens, Neoplasm | 17 | 1985 | 382 | 0.400 |
Why?
|
| Biodiversity | 1 | 2012 | 64 | 0.390 |
Why?
|
| Cells, Cultured | 21 | 2018 | 3054 | 0.390 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2007 | 295 | 0.390 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 771 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2003 | 224 | 0.370 |
Why?
|
| Macaca mulatta | 4 | 2014 | 492 | 0.370 |
Why?
|
| Creatinine | 2 | 2012 | 382 | 0.370 |
Why?
|
| Female | 69 | 2019 | 66254 | 0.370 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2012 | 193 | 0.360 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 12 | 0.360 |
Why?
|
| Oncogene Proteins, Viral | 7 | 1992 | 57 | 0.350 |
Why?
|
| Hodgkin Disease | 3 | 2005 | 294 | 0.340 |
Why?
|
| Gene Expression Regulation, Viral | 5 | 2014 | 132 | 0.330 |
Why?
|
| HIV-1 | 6 | 2005 | 463 | 0.330 |
Why?
|
| Space Flight | 3 | 2009 | 116 | 0.330 |
Why?
|
| Precancerous Conditions | 8 | 1998 | 283 | 0.320 |
Why?
|
| Adult | 28 | 2019 | 29350 | 0.320 |
Why?
|
| Carrier State | 1 | 2009 | 77 | 0.320 |
Why?
|
| Hepatitis B | 3 | 1996 | 160 | 0.310 |
Why?
|
| Bone Neoplasms | 5 | 2003 | 429 | 0.300 |
Why?
|
| Virus Activation | 3 | 2003 | 87 | 0.290 |
Why?
|
| Middle Aged | 24 | 2016 | 26363 | 0.290 |
Why?
|
| Virus Replication | 25 | 2014 | 602 | 0.290 |
Why?
|
| Male | 40 | 2019 | 60871 | 0.290 |
Why?
|
| Amino Acid Sequence | 15 | 2016 | 2697 | 0.270 |
Why?
|
| Sequence Homology, Nucleic Acid | 6 | 2008 | 286 | 0.270 |
Why?
|
| DNA, Neoplasm | 9 | 1998 | 301 | 0.270 |
Why?
|
| Cell Division | 13 | 2005 | 784 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 327 | 0.250 |
Why?
|
| Cell Membrane | 13 | 1989 | 458 | 0.250 |
Why?
|
| Genes | 7 | 1991 | 444 | 0.250 |
Why?
|
| Gamma Rays | 1 | 2005 | 49 | 0.250 |
Why?
|
| DNA Repair | 4 | 1998 | 588 | 0.250 |
Why?
|
| Open Reading Frames | 4 | 1995 | 211 | 0.240 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2003 | 230 | 0.240 |
Why?
|
| Texas | 7 | 2012 | 3586 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 9 | 2014 | 1764 | 0.240 |
Why?
|
| Meningioma | 2 | 2004 | 120 | 0.240 |
Why?
|
| Oncogenes | 5 | 2000 | 168 | 0.230 |
Why?
|
| Transfection | 7 | 2001 | 1068 | 0.230 |
Why?
|
| Medical Laboratory Personnel | 1 | 2004 | 9 | 0.230 |
Why?
|
| Phylogeny | 3 | 2016 | 696 | 0.230 |
Why?
|
| Laboratories, Hospital | 1 | 2004 | 18 | 0.230 |
Why?
|
| Choroid Plexus Neoplasms | 4 | 1998 | 14 | 0.230 |
Why?
|
| Epithelial Cells | 9 | 2010 | 902 | 0.220 |
Why?
|
| DNA Primers | 7 | 2008 | 660 | 0.220 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1036 | 0.220 |
Why?
|
| Adolescent | 13 | 2019 | 19300 | 0.220 |
Why?
|
| HIV Seronegativity | 3 | 2005 | 26 | 0.220 |
Why?
|
| Plasmids | 8 | 2005 | 514 | 0.220 |
Why?
|
| Conserved Sequence | 4 | 2005 | 293 | 0.220 |
Why?
|
| Transcriptional Activation | 4 | 2001 | 483 | 0.210 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 1996 | 61 | 0.210 |
Why?
|
| DNA Replication | 9 | 1997 | 350 | 0.210 |
Why?
|
| Virion | 1 | 2003 | 148 | 0.210 |
Why?
|
| Proto-Oncogenes | 5 | 2001 | 37 | 0.210 |
Why?
|
| Genes, Regulator | 2 | 2002 | 56 | 0.210 |
Why?
|
| Osteosarcoma | 4 | 1998 | 258 | 0.210 |
Why?
|
| Capsid Proteins | 3 | 2016 | 182 | 0.200 |
Why?
|
| Carcinogens | 3 | 2000 | 153 | 0.200 |
Why?
|
| Kidney | 21 | 2012 | 1346 | 0.200 |
Why?
|
| Heat-Shock Proteins | 3 | 1994 | 194 | 0.200 |
Why?
|
| Viral Regulatory and Accessory Proteins | 8 | 1998 | 38 | 0.200 |
Why?
|
| Incidence | 7 | 2007 | 3077 | 0.200 |
Why?
|
| Gene Expression | 5 | 2005 | 1569 | 0.200 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 1993 | 137 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2001 | 550 | 0.190 |
Why?
|
| Membrane Proteins | 6 | 1995 | 1522 | 0.190 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 68 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 270 | 0.190 |
Why?
|
| HIV Seropositivity | 2 | 2002 | 117 | 0.190 |
Why?
|
| Immunocompromised Host | 4 | 2014 | 295 | 0.180 |
Why?
|
| Zebrafish Proteins | 1 | 2001 | 111 | 0.180 |
Why?
|
| Virus Cultivation | 10 | 1995 | 76 | 0.180 |
Why?
|
| Fibroblast Growth Factors | 1 | 2001 | 153 | 0.180 |
Why?
|
| Gene Deletion | 2 | 1994 | 793 | 0.180 |
Why?
|
| Kidney Diseases | 3 | 2012 | 477 | 0.180 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 268 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 424 | 0.170 |
Why?
|
| Monkey Diseases | 2 | 2008 | 18 | 0.170 |
Why?
|
| Antibody Formation | 7 | 2009 | 259 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 120 | 0.170 |
Why?
|
| Ependymoma | 3 | 1998 | 134 | 0.170 |
Why?
|
| Mass Media | 1 | 2000 | 28 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 1992 | 370 | 0.170 |
Why?
|
| alpha 1-Antitrypsin | 2 | 1990 | 83 | 0.160 |
Why?
|
| Protein Kinases | 3 | 1986 | 332 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 247 | 0.160 |
Why?
|
| Nicaragua | 1 | 2019 | 26 | 0.160 |
Why?
|
| Colombia | 1 | 2019 | 50 | 0.160 |
Why?
|
| Biological Transport | 12 | 1987 | 346 | 0.160 |
Why?
|
| DNA Restriction Enzymes | 5 | 1997 | 120 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 51 | 0.160 |
Why?
|
| Lung Transplantation | 3 | 2009 | 318 | 0.160 |
Why?
|
| Urine | 4 | 2010 | 89 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 249 | 0.150 |
Why?
|
| Erythrocebus patas | 1 | 1998 | 4 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2002 | 2498 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 237 | 0.150 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 16 | 0.150 |
Why?
|
| Chromosome Mapping | 7 | 1994 | 1082 | 0.150 |
Why?
|
| Sequence Alignment | 3 | 2005 | 625 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 25 | 1985 | 459 | 0.150 |
Why?
|
| Binding Sites | 7 | 2014 | 1293 | 0.150 |
Why?
|
| Macaca | 1 | 1998 | 62 | 0.150 |
Why?
|
| Spleen | 3 | 2009 | 280 | 0.140 |
Why?
|
| Viral Envelope Proteins | 4 | 1995 | 151 | 0.140 |
Why?
|
| Myeloid Cells | 1 | 2018 | 100 | 0.140 |
Why?
|
| Logistic Models | 2 | 2012 | 1801 | 0.140 |
Why?
|
| Glycoproteins | 3 | 1991 | 370 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2009 | 3410 | 0.140 |
Why?
|
| DNA-Binding Proteins | 6 | 1998 | 2056 | 0.140 |
Why?
|
| Young Adult | 4 | 2019 | 8948 | 0.140 |
Why?
|
| Child | 11 | 2019 | 24466 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2019 | 4725 | 0.140 |
Why?
|
| Models, Biological | 4 | 2012 | 1461 | 0.130 |
Why?
|
| Diethylnitrosamine | 1 | 1996 | 17 | 0.130 |
Why?
|
| Alkylating Agents | 1 | 1996 | 11 | 0.130 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1996 | 62 | 0.130 |
Why?
|
| Blotting, Southern | 5 | 2003 | 215 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 422 | 0.130 |
Why?
|
| Culture Techniques | 11 | 2003 | 90 | 0.130 |
Why?
|
| Cytoplasm | 8 | 1985 | 290 | 0.130 |
Why?
|
| Molecular Weight | 12 | 1997 | 392 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 807 | 0.120 |
Why?
|
| Heterozygote | 4 | 1994 | 677 | 0.120 |
Why?
|
| Neutralization Tests | 5 | 2005 | 238 | 0.120 |
Why?
|
| Vaccination | 2 | 2019 | 953 | 0.120 |
Why?
|
| Prevalence | 3 | 2009 | 2427 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2008 | 203 | 0.120 |
Why?
|
| Antigens, Surface | 4 | 1984 | 121 | 0.120 |
Why?
|
| Viral Plaque Assay | 5 | 2004 | 42 | 0.120 |
Why?
|
| Pregnancy | 11 | 2014 | 7238 | 0.120 |
Why?
|
| Italy | 1 | 2014 | 113 | 0.120 |
Why?
|
| Peptides | 3 | 2016 | 790 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2009 | 1690 | 0.120 |
Why?
|
| Neoplasm Transplantation | 11 | 2000 | 370 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 1124 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 807 | 0.110 |
Why?
|
| Cloning, Molecular | 6 | 1997 | 892 | 0.110 |
Why?
|
| Aged | 7 | 2016 | 19383 | 0.110 |
Why?
|
| Capsid | 4 | 1998 | 142 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2014 | 176 | 0.110 |
Why?
|
| Antigens | 14 | 1971 | 157 | 0.110 |
Why?
|
| Clone Cells | 13 | 1998 | 169 | 0.110 |
Why?
|
| Protein Conformation | 6 | 1997 | 833 | 0.110 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 10 | 2000 | 56 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 32 | 0.100 |
Why?
|
| Recombination, Genetic | 5 | 2007 | 447 | 0.100 |
Why?
|
| Time Factors | 6 | 2009 | 6252 | 0.100 |
Why?
|
| Phosphoproteins | 4 | 1990 | 403 | 0.100 |
Why?
|
| Virology | 2 | 2010 | 31 | 0.100 |
Why?
|
| Epithelium | 6 | 1995 | 360 | 0.100 |
Why?
|
| Caseins | 5 | 1992 | 62 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 509 | 0.100 |
Why?
|
| Hyperplasia | 4 | 1995 | 209 | 0.100 |
Why?
|
| Epitopes | 5 | 1992 | 433 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 816 | 0.090 |
Why?
|
| Hospitalization | 1 | 1999 | 1752 | 0.090 |
Why?
|
| Palatine Tonsil | 2 | 2008 | 36 | 0.090 |
Why?
|
| Nova Scotia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Protein Binding | 2 | 1998 | 1742 | 0.090 |
Why?
|
| Neoplasm Proteins | 4 | 1999 | 669 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2001 | 4529 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 5 | 2003 | 261 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2308 | 0.090 |
Why?
|
| Alleles | 3 | 1994 | 1610 | 0.090 |
Why?
|
| Cocarcinogenesis | 2 | 2007 | 23 | 0.090 |
Why?
|
| Viral Vaccines | 2 | 2012 | 327 | 0.090 |
Why?
|
| Helper Viruses | 7 | 1978 | 45 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2040 | 0.090 |
Why?
|
| Fibroblasts | 6 | 2007 | 891 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 6440 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 1602 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 6 | 1990 | 314 | 0.090 |
Why?
|
| Phenotype | 8 | 2001 | 4253 | 0.080 |
Why?
|
| Disease Susceptibility | 3 | 2002 | 299 | 0.080 |
Why?
|
| Ribonuclease P | 1 | 2009 | 9 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 23 | 0.080 |
Why?
|
| Rabbits | 8 | 2016 | 710 | 0.080 |
Why?
|
| Retinoblastoma Protein | 2 | 2003 | 79 | 0.080 |
Why?
|
| Transformation, Genetic | 2 | 1987 | 35 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1991 | 244 | 0.080 |
Why?
|
| Transcription, Genetic | 6 | 2001 | 1701 | 0.080 |
Why?
|
| Butanols | 1 | 1989 | 3 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2002 | 276 | 0.080 |
Why?
|
| Bed Rest | 1 | 2009 | 17 | 0.080 |
Why?
|
| Mice, Transgenic | 7 | 1997 | 2416 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 1998 | 1064 | 0.080 |
Why?
|
| Nervous System Neoplasms | 1 | 1988 | 11 | 0.080 |
Why?
|
| Bird Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Virus Physiological Phenomena | 1 | 2008 | 14 | 0.080 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1988 | 81 | 0.080 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 19 | 0.080 |
Why?
|
| Papio | 1 | 2008 | 60 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 646 | 0.080 |
Why?
|
| Ganglioneuroma | 2 | 1998 | 17 | 0.080 |
Why?
|
| Birds | 1 | 2008 | 85 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2016 | 754 | 0.070 |
Why?
|
| Protein Biosynthesis | 5 | 1991 | 665 | 0.070 |
Why?
|
| Child, Preschool | 7 | 2008 | 14043 | 0.070 |
Why?
|
| Asbestos | 1 | 2007 | 14 | 0.070 |
Why?
|
| Choroid Plexus | 1 | 1987 | 24 | 0.070 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1987 | 16 | 0.070 |
Why?
|
| Oligonucleotide Probes | 2 | 2005 | 85 | 0.070 |
Why?
|
| Concanavalin A | 2 | 2005 | 15 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2008 | 270 | 0.070 |
Why?
|
| Species Specificity | 5 | 2004 | 550 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 381 | 0.070 |
Why?
|
| Brain | 3 | 2009 | 3001 | 0.070 |
Why?
|
| Carcinoma | 1 | 1989 | 280 | 0.070 |
Why?
|
| Risk Factors | 3 | 2012 | 10118 | 0.070 |
Why?
|
| Temperature | 8 | 1978 | 304 | 0.060 |
Why?
|
| Virus Integration | 2 | 1999 | 42 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2007 | 320 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 1989 | 2535 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 1237 | 0.060 |
Why?
|
| Methylation | 5 | 1990 | 226 | 0.060 |
Why?
|
| Whole-Body Irradiation | 1 | 2005 | 65 | 0.060 |
Why?
|
| Cytokines | 2 | 2009 | 1272 | 0.060 |
Why?
|
| Kazakhstan | 1 | 2005 | 8 | 0.060 |
Why?
|
| Glycosylation | 3 | 1991 | 121 | 0.060 |
Why?
|
| Virus Latency | 1 | 2005 | 61 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2005 | 228 | 0.060 |
Why?
|
| Defective Viruses | 5 | 1978 | 18 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 251 | 0.060 |
Why?
|
| Liver | 2 | 1997 | 1753 | 0.060 |
Why?
|
| Infant | 6 | 2014 | 12454 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 329 | 0.060 |
Why?
|
| Placenta | 1 | 2009 | 507 | 0.060 |
Why?
|
| Papillomaviridae | 6 | 1986 | 139 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2871 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 202 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2010 | 136 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 1994 | 52 | 0.050 |
Why?
|
| Denmark | 1 | 2003 | 34 | 0.050 |
Why?
|
| Adenocarcinoma | 3 | 2000 | 997 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1995 | 188 | 0.050 |
Why?
|
| DNA | 5 | 1992 | 1597 | 0.050 |
Why?
|
| Gadolinium | 1 | 2004 | 104 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2003 | 18 | 0.050 |
Why?
|
| Hungary | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cytochalasin B | 2 | 1984 | 9 | 0.050 |
Why?
|
| Czech Republic | 1 | 2003 | 11 | 0.050 |
Why?
|
| Age Factors | 2 | 2003 | 2812 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2001 | 319 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 1330 | 0.050 |
Why?
|
| Genotype | 2 | 2003 | 2548 | 0.050 |
Why?
|
| Histocompatibility Antigens | 2 | 1973 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2004 | 12260 | 0.050 |
Why?
|
| Genetic Vectors | 4 | 1995 | 941 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 35 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 53 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 110 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2005 | 503 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 698 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2003 | 101 | 0.050 |
Why?
|
| Saliva | 1 | 2003 | 113 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2003 | 155 | 0.050 |
Why?
|
| China | 4 | 1992 | 242 | 0.050 |
Why?
|
| Transplants | 1 | 2002 | 35 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 657 | 0.050 |
Why?
|
| Adenoviruses, Human | 2 | 1986 | 81 | 0.050 |
Why?
|
| Immune System | 1 | 2003 | 87 | 0.050 |
Why?
|
| Apoptosis | 3 | 1998 | 1791 | 0.050 |
Why?
|
| Luciferases | 2 | 2000 | 136 | 0.050 |
Why?
|
| Hybridization, Genetic | 5 | 1984 | 20 | 0.050 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2001 | 10 | 0.050 |
Why?
|
| Leucovorin | 1 | 2002 | 50 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 22 | 0.050 |
Why?
|
| Cytopathogenic Effect, Viral | 4 | 1995 | 29 | 0.050 |
Why?
|
| Methionine | 3 | 1988 | 103 | 0.050 |
Why?
|
| Wnt1 Protein | 1 | 2001 | 71 | 0.050 |
Why?
|
| Bleomycin | 1 | 2002 | 150 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2005 | 3257 | 0.050 |
Why?
|
| Cytosine | 3 | 1987 | 56 | 0.050 |
Why?
|
| Seasons | 1 | 2003 | 308 | 0.050 |
Why?
|
| Urban Health | 1 | 2001 | 73 | 0.050 |
Why?
|
| Cell Cycle | 3 | 1994 | 619 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 274 | 0.050 |
Why?
|
| Vincristine | 1 | 2002 | 196 | 0.050 |
Why?
|
| Templates, Genetic | 2 | 1997 | 97 | 0.040 |
Why?
|
| Cadherins | 1 | 2001 | 164 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2001 | 195 | 0.040 |
Why?
|
| Immunization | 3 | 2009 | 307 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2002 | 301 | 0.040 |
Why?
|
| beta Catenin | 1 | 2001 | 205 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2003 | 389 | 0.040 |
Why?
|
| Switzerland | 1 | 2000 | 16 | 0.040 |
Why?
|
| Complement Fixation Tests | 8 | 1979 | 33 | 0.040 |
Why?
|
| Kinetics | 4 | 1991 | 1321 | 0.040 |
Why?
|
| Finland | 1 | 2000 | 42 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 1991 | 169 | 0.040 |
Why?
|
| Lactation | 3 | 1989 | 194 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2009 | 6086 | 0.040 |
Why?
|
| Immune Sera | 4 | 1985 | 95 | 0.040 |
Why?
|
| Tubulin | 2 | 1991 | 102 | 0.040 |
Why?
|
| Precipitin Tests | 3 | 1989 | 151 | 0.040 |
Why?
|
| Transplantation Immunology | 4 | 1973 | 53 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 421 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 352 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 308 | 0.040 |
Why?
|
| DNA Probes | 2 | 1989 | 124 | 0.040 |
Why?
|
| Cycloheximide | 3 | 1988 | 43 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 384 | 0.040 |
Why?
|
| Oncogene Proteins | 2 | 1990 | 137 | 0.040 |
Why?
|
| RNA, Messenger | 6 | 1992 | 2821 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 354 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 130 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 1999 | 113 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 1998 | 86 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1998 | 81 | 0.040 |
Why?
|
| Hepadnaviridae | 1 | 1997 | 3 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1998 | 123 | 0.040 |
Why?
|
| Sequence Homology | 1 | 1997 | 62 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 33 | 0.040 |
Why?
|
| Retroviridae Proteins | 2 | 1987 | 13 | 0.040 |
Why?
|
| Hydrocortisone | 3 | 1992 | 220 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 49 | 0.030 |
Why?
|
| Age Distribution | 1 | 1998 | 411 | 0.030 |
Why?
|
| H-2 Antigens | 3 | 1998 | 24 | 0.030 |
Why?
|
| Galactose | 2 | 1988 | 54 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 206 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 4344 | 0.030 |
Why?
|
| Microscopy, Electron | 6 | 1980 | 395 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3336 | 0.030 |
Why?
|
| Cell Differentiation | 4 | 1990 | 1935 | 0.030 |
Why?
|
| Photoreceptor Cells | 1 | 1997 | 91 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 1996 | 21 | 0.030 |
Why?
|
| Embryo, Mammalian | 6 | 1986 | 455 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 131 | 0.030 |
Why?
|
| Genomics | 1 | 2004 | 1486 | 0.030 |
Why?
|
| Gene Products, tax | 1 | 1996 | 46 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 1392 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2007 | 16208 | 0.030 |
Why?
|
| Genetics, Microbial | 3 | 1972 | 6 | 0.030 |
Why?
|
| Phosphorylation | 4 | 1986 | 1623 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1996 | 48 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1997 | 162 | 0.030 |
Why?
|
| Cell Compartmentation | 2 | 1986 | 42 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 1977 | 178 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 1997 | 270 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 2014 | 528 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Genes, tat | 1 | 1995 | 10 | 0.030 |
Why?
|
| Superantigens | 1 | 1995 | 20 | 0.030 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 2 | 1985 | 3 | 0.030 |
Why?
|
| Acetylglucosaminidase | 2 | 1985 | 17 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 259 | 0.030 |
Why?
|
| Adenoviruses, Simian | 1 | 1975 | 1 | 0.030 |
Why?
|
| Yeasts | 1 | 1995 | 42 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1999 | 435 | 0.030 |
Why?
|
| Locus Control Region | 1 | 2014 | 8 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1998 | 501 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5094 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1996 | 808 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3047 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 1015 | 0.030 |
Why?
|
| Phosphopeptides | 2 | 1984 | 27 | 0.030 |
Why?
|
| Mumps | 1 | 1974 | 11 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 1994 | 13 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 6 | 1983 | 396 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 129 | 0.030 |
Why?
|
| Multigene Family | 1 | 1995 | 298 | 0.030 |
Why?
|
| Prolactin | 2 | 1992 | 113 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 147 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1996 | 1688 | 0.030 |
Why?
|
| Ultraviolet Rays | 4 | 1998 | 204 | 0.030 |
Why?
|
| Lens, Crystalline | 1 | 1994 | 136 | 0.030 |
Why?
|
| Mice, Inbred Strains | 4 | 1984 | 312 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1994 | 463 | 0.030 |
Why?
|
| Half-Life | 1 | 1993 | 156 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1994 | 132 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1994 | 347 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 1271 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3572 | 0.030 |
Why?
|
| Solubility | 2 | 1986 | 132 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1071 | 0.020 |
Why?
|
| Chromosome Disorders | 2 | 1972 | 312 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 1994 | 196 | 0.020 |
Why?
|
| Chromosome Aberrations | 3 | 1972 | 621 | 0.020 |
Why?
|
| Codon | 1 | 1992 | 96 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1974 | 226 | 0.020 |
Why?
|
| DEAE-Dextran | 3 | 1977 | 5 | 0.020 |
Why?
|
| Baculoviridae | 1 | 1991 | 64 | 0.020 |
Why?
|
| Microsomes | 1 | 1991 | 55 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1991 | 63 | 0.020 |
Why?
|
| Insecta | 1 | 1991 | 57 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1996 | 1182 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1999 | 1892 | 0.020 |
Why?
|
| Deoxyglucose | 3 | 1976 | 30 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 1676 | 0.020 |
Why?
|
| Colchicine | 1 | 1991 | 43 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 569 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1991 | 59 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 143 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 5 | 1998 | 4427 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1991 | 78 | 0.020 |
Why?
|
| Proviruses | 1 | 1990 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1991 | 93 | 0.020 |
Why?
|
| Aldosterone | 1 | 1990 | 60 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 788 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1991 | 150 | 0.020 |
Why?
|
| Microtubules | 1 | 1991 | 197 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 1458 | 0.020 |
Why?
|
| Hybrid Cells | 2 | 1988 | 80 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1994 | 364 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1990 | 314 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2010 | 108 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1991 | 355 | 0.020 |
Why?
|
| Lung | 4 | 1971 | 1485 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 452 | 0.020 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1987 | 384 | 0.020 |
Why?
|
| 1-Butanol | 1 | 1989 | 2 | 0.020 |
Why?
|
| Peptide Fragments | 3 | 1994 | 750 | 0.020 |
Why?
|
| Poly A | 2 | 1979 | 59 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 30 | 0.020 |
Why?
|
| Carbohydrate Conformation | 1 | 1988 | 16 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1989 | 289 | 0.020 |
Why?
|
| Antimetabolites | 2 | 1965 | 33 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 1988 | 44 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 54 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 648 | 0.020 |
Why?
|
| Survival Rate | 1 | 1994 | 2018 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1991 | 250 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 53 | 0.020 |
Why?
|
| Papio ursinus | 1 | 2008 | 1 | 0.020 |
Why?
|
| Papio anubis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Papio cynocephalus | 1 | 2008 | 3 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 12 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 33 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 2 | 1978 | 15 | 0.020 |
Why?
|
| Monensin | 1 | 1987 | 10 | 0.020 |
Why?
|
| United States | 1 | 2003 | 10754 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 345 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1991 | 282 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 1987 | 93 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2007 | 57 | 0.020 |
Why?
|
| Immunoassay | 1 | 1987 | 128 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1987 | 139 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 530 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 1986 | 19 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1013 | 0.020 |
Why?
|
| Metaplasia | 1 | 1987 | 215 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1996 | 2603 | 0.020 |
Why?
|
| RNA | 2 | 1985 | 568 | 0.020 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1986 | 9 | 0.020 |
Why?
|
| Genetic Code | 2 | 1999 | 40 | 0.020 |
Why?
|
| Research | 5 | 1965 | 263 | 0.020 |
Why?
|
| Viral Fusion Proteins | 1 | 1986 | 77 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2005 | 4 | 0.020 |
Why?
|
| Costa Rica | 1 | 2005 | 13 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 1245 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 1989 | 469 | 0.020 |
Why?
|
| Germinal Center | 1 | 2005 | 38 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1985 | 11 | 0.020 |
Why?
|
| Prognosis | 1 | 1995 | 4547 | 0.020 |
Why?
|
| Tunicamycin | 1 | 1985 | 7 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 43 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 1985 | 15 | 0.020 |
Why?
|
| Glucosamine | 1 | 1985 | 12 | 0.020 |
Why?
|
| Mannose | 1 | 1985 | 19 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1985 | 185 | 0.020 |
Why?
|
| Exocytosis | 1 | 1985 | 63 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1985 | 202 | 0.010 |
Why?
|
| Rats | 2 | 1997 | 3686 | 0.010 |
Why?
|
| Polyomaviridae | 3 | 1974 | 3 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1986 | 211 | 0.010 |
Why?
|
| Octoxynol | 1 | 1984 | 7 | 0.010 |
Why?
|
| Leupeptins | 1 | 1984 | 26 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 141 | 0.010 |
Why?
|
| Iodoproteins | 1 | 1984 | 1 | 0.010 |
Why?
|
| Growth Substances | 1 | 1984 | 113 | 0.010 |
Why?
|
| Glycosides | 1 | 1983 | 7 | 0.010 |
Why?
|
| Fucose | 1 | 1983 | 21 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1987 | 1217 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 1997 | 1340 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 297 | 0.010 |
Why?
|
| Microinjections | 2 | 1997 | 52 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1995 | 8172 | 0.010 |
Why?
|
| Isoelectric Point | 2 | 1980 | 18 | 0.010 |
Why?
|
| Papilloma | 2 | 1973 | 25 | 0.010 |
Why?
|
| Nephritis | 1 | 2002 | 20 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1982 | 26 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 223 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 2 | 1973 | 79 | 0.010 |
Why?
|
| Cystitis | 1 | 2002 | 50 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1981 | 25 | 0.010 |
Why?
|
| Pituitary Hormones | 1 | 1981 | 3 | 0.010 |
Why?
|
| Urethane | 1 | 1981 | 5 | 0.010 |
Why?
|
| Methylcellulose | 1 | 1981 | 5 | 0.010 |
Why?
|
| X-Rays | 1 | 1981 | 27 | 0.010 |
Why?
|
| Subcellular Fractions | 2 | 1979 | 98 | 0.010 |
Why?
|
| Homozygote | 2 | 1993 | 532 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1504 | 0.010 |
Why?
|
| Tissue Culture Techniques | 3 | 1965 | 69 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 686 | 0.010 |
Why?
|
| Amino Acids | 1 | 1983 | 663 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1980 | 3 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 2972 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 1241 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1980 | 36 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 110 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3366 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2000 | 86 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 1118 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 540 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1980 | 99 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2000 | 154 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2002 | 458 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1978 | 46 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 3 | 1972 | 331 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 80 | 0.010 |
Why?
|
| Calcium | 1 | 1984 | 1101 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 1978 | 3 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1989 | 99 | 0.010 |
Why?
|
| In Vitro Techniques | 3 | 1997 | 969 | 0.010 |
Why?
|
| Tritium | 3 | 1974 | 173 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1977 | 22 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1977 | 87 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 78 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1978 | 136 | 0.010 |
Why?
|
| Symbiosis | 1 | 1998 | 65 | 0.010 |
Why?
|
| Rod Opsins | 1 | 1997 | 16 | 0.010 |
Why?
|
| Viral Interference | 1 | 1977 | 6 | 0.010 |
Why?
|
| Peptide Biosynthesis | 1 | 1977 | 19 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1977 | 118 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 125 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1997 | 30 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 37 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1997 | 95 | 0.010 |
Why?
|
| Cells | 1 | 1977 | 27 | 0.010 |
Why?
|
| Retroviridae | 1 | 1977 | 196 | 0.010 |
Why?
|
| Antibodies | 2 | 1971 | 372 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1999 | 350 | 0.010 |
Why?
|
| Warts | 2 | 1973 | 11 | 0.010 |
Why?
|
| Agglutination | 1 | 1976 | 3 | 0.010 |
Why?
|
| Detergents | 1 | 1976 | 24 | 0.010 |
Why?
|
| Deoxyribonucleases | 2 | 1974 | 26 | 0.010 |
Why?
|
| Proteins | 1 | 1982 | 1041 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 1289 | 0.010 |
Why?
|
| Dextrans | 2 | 1974 | 45 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1997 | 287 | 0.010 |
Why?
|
| Adenoviridae Infections | 2 | 1966 | 70 | 0.010 |
Why?
|
| Morphogenesis | 2 | 1989 | 212 | 0.010 |
Why?
|
| Thymidine | 2 | 1974 | 54 | 0.010 |
Why?
|
| 5-Methylcytosine | 2 | 1987 | 32 | 0.010 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 1 | 1995 | 1 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 3 | 1974 | 97 | 0.010 |
Why?
|
| Cross Reactions | 2 | 1973 | 193 | 0.010 |
Why?
|
| Gene Products, rev | 1 | 1995 | 11 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1997 | 709 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 17 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1995 | 28 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 30 | 0.010 |
Why?
|
| Contact Inhibition | 1 | 1975 | 2 | 0.010 |
Why?
|
| Potassium | 1 | 1976 | 280 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1975 | 87 | 0.010 |
Why?
|
| Surface Properties | 1 | 1975 | 76 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1975 | 60 | 0.010 |
Why?
|
| DNA Damage | 1 | 1998 | 515 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 247 | 0.010 |
Why?
|
| Mumps virus | 1 | 1974 | 4 | 0.010 |
Why?
|
| Parotitis | 1 | 1974 | 5 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1974 | 65 | 0.010 |
Why?
|
| Dimethylnitrosamine | 1 | 1993 | 2 | 0.010 |
Why?
|
| Eye Abnormalities | 1 | 1994 | 106 | 0.010 |
Why?
|
| Condylomata Acuminata | 1 | 1973 | 15 | 0.010 |
Why?
|
| Meningitis | 1 | 1974 | 98 | 0.010 |
Why?
|
| Fibroma | 1 | 1973 | 30 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1973 | 13 | 0.010 |
Why?
|
| Eye | 1 | 1994 | 227 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1995 | 1107 | 0.010 |
Why?
|
| Adenovirus Early Proteins | 1 | 1992 | 4 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 147 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1972 | 38 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1992 | 30 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1972 | 51 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1972 | 32 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 768 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1992 | 121 | 0.010 |
Why?
|
| Blastocyst | 1 | 1992 | 78 | 0.010 |
Why?
|
| Skin | 1 | 1975 | 511 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1971 | 19 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1974 | 325 | 0.010 |
Why?
|
| Idoxuridine | 2 | 1973 | 6 | 0.010 |
Why?
|
| Acute Disease | 1 | 1974 | 1098 | 0.010 |
Why?
|
| Exons | 1 | 1992 | 795 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1991 | 311 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1989 | 192 | 0.000 |
Why?
|
| Gentamicins | 1 | 1989 | 95 | 0.000 |
Why?
|
| Histones | 1 | 1992 | 540 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1971 | 1005 | 0.000 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1991 | 373 | 0.000 |
Why?
|
| Stem Cells | 1 | 1992 | 702 | 0.000 |
Why?
|
| Genetics | 1 | 1967 | 25 | 0.000 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1986 | 6 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1994 | 3755 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1986 | 103 | 0.000 |
Why?
|
| Floxuridine | 1 | 1965 | 9 | 0.000 |
Why?
|
| Puromycin | 1 | 1965 | 11 | 0.000 |
Why?
|
| Nucleosides | 1 | 1965 | 17 | 0.000 |
Why?
|
| Pharmacology | 1 | 1965 | 10 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1965 | 67 | 0.000 |
Why?
|
| Fluorescence | 1 | 1965 | 93 | 0.000 |
Why?
|
| Mitomycin | 1 | 1965 | 49 | 0.000 |
Why?
|
| Fluorouracil | 1 | 1965 | 129 | 0.000 |
Why?
|
| Phenylalanine | 1 | 1965 | 124 | 0.000 |
Why?
|
| Microscopy | 1 | 1965 | 117 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1986 | 623 | 0.000 |
Why?
|
| Hormones | 1 | 1985 | 190 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1983 | 41 | 0.000 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1985 | 217 | 0.000 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 1974 | 44 | 0.000 |
Why?
|
| Cell Aggregation | 1 | 1981 | 22 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1983 | 226 | 0.000 |
Why?
|
| Body Weight | 1 | 1985 | 1009 | 0.000 |
Why?
|
| Castration | 1 | 1980 | 33 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1980 | 48 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1989 | 2411 | 0.000 |
Why?
|
| Ovary | 1 | 1980 | 391 | 0.000 |
Why?
|
| Pronase | 1 | 1974 | 4 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1974 | 24 | 0.000 |
Why?
|
| Ribonucleases | 1 | 1974 | 52 | 0.000 |
Why?
|
| Trypsin | 1 | 1974 | 95 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1974 | 75 | 0.000 |
Why?
|
| Laryngeal Diseases | 1 | 1973 | 31 | 0.000 |
Why?
|
| Phenols | 1 | 1974 | 58 | 0.000 |
Why?
|
| Genital Diseases, Male | 1 | 1973 | 12 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 184 | 0.000 |
Why?
|
| Genital Diseases, Female | 1 | 1973 | 30 | 0.000 |
Why?
|
| Pancreas | 1 | 1974 | 216 | 0.000 |
Why?
|
| Dogs | 1 | 1974 | 765 | 0.000 |
Why?
|
| Cattle | 1 | 1974 | 563 | 0.000 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1973 | 93 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1974 | 228 | 0.000 |
Why?
|
| Uridine | 1 | 1971 | 34 | 0.000 |
Why?
|
| Pregnancy Complications | 1 | 1973 | 506 | 0.000 |
Why?
|
| Measles virus | 1 | 1966 | 10 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1966 | 104 | 0.000 |
Why?
|